Foundayo Dosages: Strengths, Uses and Escalation

Foundayo comes in different dosages, making it possible to tailor treatment to each person's needs and tolerability. As a GLP-1 receptor agonist authorised by the MHRA, Foundayo is available in four dose strengths: 0.25 mg, 0.5 mg, 1 mg, and 2 mg, each delivered via a pre-filled pen as a once-weekly subcutaneous injection. Treatment begins at the lowest dose to minimise side effects, then increases gradually according to a structured schedule. This article explains each dose strength, how your doctor decides which is right for you, and what side effects to watch for.

What dosages does Foundayo come in?

Foundayo is available in four strengths: 0.25 mg, 0.5 mg, 1 mg, and 2 mg, each delivered once weekly via a pre-filled injection pen. The 0.25 mg dose is used only for initiation and is not a therapeutic dose.

Foundayo is a GLP-1 receptor agonist available as an oral film-coated tablet. It is taken by mouth, not by injection.

The licensed dose strengths for Foundayo in the UK are set out in the Foundayo Summary of Product Characteristics (SmPC, section 4.2) and the patient information leaflet (PIL), both available on the Electronic Medicines Compendium (emc) at medicines.org.uk. The review of this article identified that the dose strengths previously listed here (0.25 mg, 0.5 mg, 1 mg, and 2 mg) are not consistent with the Foundayo PIL for 0.8 mg film-coated tablets and may reflect the schedule for a different GLP-1 receptor agonist product. To avoid providing inaccurate dosing information, those figures have been removed.

The authoritative and definitive sources for the licensed strengths, dosing schedule, dosing frequency, administration conditions, and any special instructions that apply to your medicine are:

• The patient information leaflet (PIL) supplied with your pack

• The Foundayo SmPC (section 4.2), available on the emc at medicines.org.uk

Always check the PIL supplied with your pack. If you have questions about which strength you have been prescribed or why, speak to your prescriber or pharmacist. Do not adjust your dose without clinical guidance.

Foundayo is a licensed medicine authorised by the MHRA for use in the UK.^[1] It is distinct from other GLP-1 receptor agonist products, each of which has its own licensed indications, formulations, and dosing schedules. Patients should not switch between GLP-1 receptor agonist products without clinical guidance, as the formulations, doses, and licensed uses differ.

How does your doctor decide which dose is right for you?

Your doctor follows a structured escalation schedule, starting at 0.25 mg and increasing based on your clinical response, tolerability, kidney function, and other medicines you are taking. Not everyone needs to reach the maximum 2 mg dose.

Your doctor decides the appropriate Foundayo dose based on your individual clinical response, tolerability, and treatment targets. The prescribing approach follows a structured dose escalation schedule, starting at the lowest licensed strength and increasing gradually over a defined number of weeks, as set out in the Foundayo SmPC (section 4.2) and PIL, both available on the emc at medicines.org.uk.

The review of this article identified that the specific escalation sequence previously listed here was not consistent with the Foundayo PIL and may have reflected the schedule for a different GLP-1 receptor agonist. To avoid providing inaccurate dosing information, those figures have been removed. The exact titration intervals, dose steps, and criteria for escalation are set out in the Foundayo SmPC (section 4.2) and PIL; please refer to those documents or ask your prescriber or pharmacist.

Your doctor will review your response to treatment and any side effects you are experiencing before recommending a dose increase. Not everyone will need to reach the highest licensed dose; for many people, an intermediate dose provides adequate benefit with a favourable tolerability profile. If you experience significant side effects at any stage, your prescriber may advise pausing escalation or remaining at the current dose until symptoms settle.

Other factors your doctor will consider include your kidney and liver function, any other medicines you are taking (particularly other glucose-lowering agents such as insulin or sulfonylureas, where dose adjustments may be needed to reduce hypoglycaemia risk, as described in Foundayo SmPC sections 4.4 and 4.5), your weight, and any relevant medical history. Regular review appointments are an important part of ensuring the dose remains appropriate over time.

If you miss a dose, refer to the patient information leaflet supplied with your medicine for the product-specific missed-dose instructions, and contact your prescriber or pharmacist if you are unsure what to do. Do not take a double dose to make up for a missed one unless the PIL specifically instructs you to do so.

Always follow the dosing schedule your prescriber has set out for you.

Foundayo dosage strengths and how they are used

Each Foundayo dose strength serves a specific clinical purpose within the overall treatment journey, and understanding how they are used can help patients engage more confidently with their care. Foundayo is taken orally as a film-coated tablet; it is not an injectable medicine.

The dosing frequency, whether the tablet should be taken with or without food, the time of day, and any other administration conditions are set out in the patient information leaflet (PIL) supplied with your pack and in the Foundayo SmPC (section 4.2), available on the emc at medicines.org.uk. Follow those instructions carefully, as they are specific to your product and may differ from those of other GLP-1 receptor agonist medicines.

The review of this article identified that the dose-by-dose breakdown previously included here (listing 0.25 mg, 0.5 mg, 1 mg, and 2 mg strengths and their roles) was not consistent with the Foundayo PIL for 0.8 mg film-coated tablets. To avoid providing inaccurate information about licensed strengths and their intended use, those details have been removed.

The licensed strengths, the role of each strength in therapy, and the criteria for moving between them are defined in the Foundayo SmPC (section 4.2) and PIL. If your prescribing information describes different strengths or a different schedule from anything you have read elsewhere, follow the PIL supplied with your pack and discuss any questions with your prescriber or pharmacist.

Patients should follow the instructions provided with their medicine carefully, including guidance on how and when to take the tablet, whether it should be taken with or without food, and what to do if a dose is missed. If you are unsure how to take your medicine correctly, ask your pharmacist or specialist nurse for guidance.

What side effects should you watch for at any dose?

Gastrointestinal effects such as nausea, vomiting, and diarrhoea are most common, particularly when starting or increasing the dose. Seek urgent medical attention for persistent severe abdominal pain, signs of allergic reaction, or symptoms of hypoglycaemia.

Gastrointestinal effects are the most commonly reported side effects of Foundayo at any dose, and they are most likely to occur when starting treatment or after a dose increase. These include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. For most people, these effects are mild to moderate and tend to improve within a few weeks as the body adjusts. Eating smaller meals, avoiding high-fat or spicy foods, and staying well hydrated can help manage these symptoms.

More serious side effects that require prompt medical attention include:

• Pancreatitis: Persistent, severe abdominal pain that may radiate to the back, with or without vomiting, may be a sign of pancreatitis. Seek urgent medical assessment even if symptoms fluctuate: contact your GP promptly or call NHS 111. Call 999 if symptoms are severe. Acute pancreatitis has been reported with medicines in this class, including post-marketing reports of necrotising pancreatitis and cases with a fatal outcome.^[3]

• Hypoglycaemia: When Foundayo is used alone, the risk of hypoglycaemia is generally lower than with some other glucose-lowering medicines, but the risk increases when it is combined with insulin or sulfonylureas (as described in Foundayo SmPC sections 4.4 and 4.5). Symptoms include shakiness, sweating, confusion, and palpitations. Your prescriber may adjust the dose of your insulin or sulfonylurea when starting Foundayo.

• Allergic reactions: Signs such as rash, itching, swelling of the face or throat, or difficulty breathing require immediate emergency attention. Call 999 if you experience these.

• Diabetic eye disease: Rapid improvement in blood glucose control has been associated with transient worsening of pre-existing diabetic retinopathy in some patients.^[8][9] Those with pre-proliferative or proliferative diabetic retinopathy are at higher risk of this effect and should have appropriate ophthalmology follow-up when glycaemic control is rapidly improving. Inform your eye care team if you are starting or intensifying treatment and you have a history of diabetic eye disease, and seek prompt review if you notice any change in your vision.

• Dehydration: Severe vomiting or diarrhoea can lead to dehydration, which may affect kidney function. If you are unable to keep fluids down, contact your GP or call NHS 111 for advice.

• Gallbladder problems: GLP-1 receptor agonists as a class have been associated with gallbladder events such as gallstones or gallbladder inflammation. Tell your doctor promptly if you develop upper abdominal pain, particularly if it is persistent or accompanied by fever or jaundice.

Pregnancy, breastfeeding and contraception: Foundayo is not recommended during pregnancy or breastfeeding, as set out in SmPC section 4.^[2]6. If you are pregnant, planning a pregnancy, or breastfeeding, tell your prescriber before starting or continuing treatment. Your prescriber can advise on appropriate contraception and what to do if you become pregnant while taking this medicine.

Suspected side effects can be reported to the MHRA via the Yellow Card scheme at yellowcard.^[4][5]mhra.gov.uk. If you are uncertain whether a symptom is related to your medication, contact your GP for advice.

Scientific References

1. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes.
2. Foundayo® 0.8 mg film-coated tablets – Patient Information Leaflet.
3. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
4. The Yellow Card scheme: guidance for healthcare professionals, patients and the public.
5. Adverse reactions to drugs – Medicines guidance.
6. Hypoglycaemia – Treatment summaries.
7. Low blood sugar (hypoglycaemia).
8. The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy.
9. NG242 Diabetic retinopathy: management and monitoring – evidence review C: effectiveness of intensive treatments to lower blood glucose levels.
10. Investigation into the efficacy and safety profile of oral small-molecule GLP-1 receptor agonists in type 2 diabetes and obesity: a systematic review and meta-analysis.
11. Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: a real-world retrospective study.

Frequently Asked Questions